HC Wainwright Has Bullish Forecast for MBOT Q2 Earnings

Microbot Medical Inc. (NASDAQ:MBOT) – Research analysts at HC Wainwright upped their Q2 2025 earnings per share (EPS) estimates for shares of Microbot Medical in a research note issued on Tuesday, June 10th. HC Wainwright analyst R. Selvaraju now forecasts that the biotechnology company will earn ($0.08) per share for the quarter, up from their prior forecast of ($0.12). HC Wainwright currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for Microbot Medical’s current full-year earnings is ($0.71) per share. HC Wainwright also issued estimates for Microbot Medical’s Q3 2025 earnings at ($0.08) EPS and FY2025 earnings at ($0.32) EPS.

Microbot Medical (NASDAQ:MBOT) last issued its quarterly earnings data on Wednesday, May 21st. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.07.

Microbot Medical Stock Performance

Shares of MBOT opened at $2.50 on Thursday. The stock’s 50-day simple moving average is $2.42 and its 200 day simple moving average is $1.84. The stock has a market capitalization of $90.95 million, a price-to-earnings ratio of -3.12 and a beta of 1.14. Microbot Medical has a 52-week low of $0.82 and a 52-week high of $3.38.

Institutional Trading of Microbot Medical

A number of institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC lifted its holdings in Microbot Medical by 7.9% during the 4th quarter. Geode Capital Management LLC now owns 142,659 shares of the biotechnology company’s stock worth $160,000 after purchasing an additional 10,442 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in Microbot Medical during the 4th quarter worth about $118,000. Goldman Sachs Group Inc. purchased a new stake in Microbot Medical during the 1st quarter worth about $57,000. Finally, Virtu Financial LLC purchased a new stake in shares of Microbot Medical in the 1st quarter valued at about $42,000. Hedge funds and other institutional investors own 16.30% of the company’s stock.

Microbot Medical Company Profile

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.